# ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

Source: https://onco.cc/trials/nct05682443/  
OnCo record `nct05682443` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Gotistobart, Lutetium-177 vipivotide tetraxetan in prostate cancer, run by OncoC4, Inc., active and no longer recruiting.

## Summary

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC is a phase 1/2 interventional study registered as NCT05682443 by OncoC4, Inc., with 148 participants enrolled, started 2023-12-11 and due to reach its primary completion in 2026-11-30. Interventions recorded: ONC-392 low, ONC-392 high, lutetium Lu 177 vipivotide tetraxetan. Conditions listed: Metastatic Castration-resistant Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05682443
- Phase: 1/2
- Setting: Randomized Study of ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Progressed on Androgen Receptor (AR) Pathway Inhibition
- Sponsor: OncoC4, Inc.
- Enrolled: 148

## Sources

- ClinicalTrials.gov NCT05682443: https://clinicaltrials.gov/study/NCT05682443

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Gotistobart](https://onco.cc/drugs/gotistobart/), [Lutetium-177 vipivotide tetraxetan](https://onco.cc/drugs/pluvicto/)
- companies: [OncoC4](https://onco.cc/companies/oncoc4/)

---
JSON: https://onco.cc/api/v1/entities/nct05682443.json